Physician profile
Ellen Sinclair Webber
NPI 1861429458
$3,421.88
in general payments reported to CMS, 2019-2025
40 companies · $843 in 2025
The $843 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.71 · 2020: $311 · 2021: $415 · 2022: $537 · 2023: $443 · 2024: $796 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073 · Education: $8.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.21 |
| Education | $8.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $571.86 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $474.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $432.80 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $338.68 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $254.37 | 2021-2025 | Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.11 | 2019-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.66 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $76.92 | 2022-2025 | Zoryve, Livalo |
| Janssen Pharmaceuticals, INC | $69.19 | 2020-2022 | |
| Sanofi Pasteur INC. | $67.60 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $66.16 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $62.61 | 2019-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $59.97 | 2022-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $59.35 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $53.70 | 2020-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Sinclair Webber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.